Marc Allan Pfeffer
#68,526
Most Influential Person Now
Marc Allan Pfeffer's AcademicInfluence.com Rankings
Marc Allan Pfeffermedical Degrees
Medical
#517
World Rank
#702
Historical Rank
Cardiology
#18
World Rank
#18
Historical Rank
Epidemiology
#56
World Rank
#62
Historical Rank
Marc Allan Pfefferphilosophy Degrees
Philosophy
#2235
World Rank
#3869
Historical Rank
Logic
#494
World Rank
#914
Historical Rank
Download Badge
Medical Philosophy
Marc Allan Pfeffer's Degrees
- Bachelors Biology Stanford University
- Doctorate Medicine Harvard University
Similar Degrees You Can Earn
Why Is Marc Allan Pfeffer Influential?
(Suggest an Edit or Addition)Marc Allan Pfeffer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. (1996) (6618)
- Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. (1992) (5870)
- Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. (2003) (4087)
- Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. (1990) (2868)
- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial (2003) (2785)
- Cardiac-resynchronization therapy for the prevention of heart-failure events. (2009) (2617)
- Intensive versus moderate lipid lowering with statins after acute coronary syndromes. (2004) (2522)
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial (2003) (2428)
- Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. (2003) (2366)
- C-reactive protein levels and outcomes after statin therapy. (2005) (2243)
- AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. (2006) (2183)
- Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention (2005) (2002)
- Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. (2004) (1917)
- Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial (2006) (1889)
- Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme (2003) (1871)
- Effect of clopidogrel added to aspirin in patients with atrial fibrillation. (2009) (1867)
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. (2015) (1755)
- Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. (2003) (1718)
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 (2020) (1664)
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial (2003) (1573)
- Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients (2000) (1551)
- Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. (1998) (1476)
- Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein (1999) (1460)
- Myocardial Infarct Size and Ventricular Function in Rats (1979) (1380)
- Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. (2004) (1346)
- AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. (2006) (1221)
- Cardiorenal end points in a trial of aliskiren for type 2 diabetes. (2012) (1133)
- Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. (1988) (1113)
- A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. (2009) (1106)
- Angiotensin-converting-enzyme inhibition in stable coronary artery disease. (2004) (1095)
- Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. (2019) (1066)
- Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. (1998) (1015)
- Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. (1998) (979)
- Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. (2000) (958)
- A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. (1995) (954)
- Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications (1990) (940)
- Influence of Chronic Captopril Therapy on the Infarcted Left Ventricle of the Rat (1985) (896)
- Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. (2007) (887)
- Predictors of mortality and morbidity in patients with chronic heart failure. (2006) (882)
- Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure (2006) (859)
- Quantitative Two-Dimensional Echocardiographic Measurements are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction: The Protective Effect of Captopril (1994) (847)
- A sensitive cardiac troponin T assay in stable coronary artery disease. (2009) (827)
- Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease (2005) (799)
- Controversies in ventricular remodelling (2006) (795)
- Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. (2005) (773)
- Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. (1986) (751)
- AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. (2001) (723)
- Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial (2015) (709)
- Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients (2005) (686)
- Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. (1997) (668)
- Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. (1998) (632)
- AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. (2001) (628)
- Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease (2008) (612)
- Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. (1999) (593)
- Ventricular dysfunction and the risk of stroke after myocardial infarction. (1997) (579)
- Increased pulse pressure and risk of heart failure in the elderly. (1999) (569)
- Progressive ventricular remodeling in rat with myocardial infarction. (1991) (559)
- Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure (2007) (535)
- Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. (1997) (533)
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. (2008) (529)
- Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. (2006) (515)
- Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. (1997) (501)
- VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial (2000) (478)
- Red blood cell distribution width and mortality risk in a community-based prospective cohort. (2009) (472)
- Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. (2007) (462)
- Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial (2005) (459)
- Treatment of anemia with darbepoetin alfa in systolic heart failure. (2013) (439)
- Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. (1999) (432)
- Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. (2002) (424)
- Isolated systolic hypertension : prognostic information provided by pulse pressure. (1999) (422)
- Erythropoietic response and outcomes in kidney disease and type 2 diabetes. (2010) (421)
- Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy (2003) (404)
- Left Ventricular Diastolic Pressure‐Volume Relations in Rats with Healed Myocardial Infarction: Effects on Systolic Function (1981) (384)
- Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial (2000) (384)
- Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. (1998) (381)
- Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease (2004) (377)
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
- Heart Failure With Preserved Ejection Fraction In Perspective. (2019) (369)
- Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. (1971) (368)
- Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. (2016) (353)
- Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials (2004) (349)
- Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. (1994) (348)
- Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease (2007) (347)
- Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. (2005) (341)
- Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) (2003) (341)
- Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone (2015) (336)
- Body Mass Index and Prognosis in Patients With Chronic Heart Failure: Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program (2007) (336)
- Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program (2009) (328)
- Biomarkers of inflammation and progression of chronic kidney disease. (2005) (322)
- Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: Baseline Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (2014) (320)
- New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. (2014) (318)
- Developing therapies for heart failure with preserved ejection fraction: current state and future directions. (2014) (317)
- Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system (2007) (314)
- A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. (1993) (314)
- Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. (2009) (311)
- Effect of Cardiac Resynchronization Therapy on Reverse Remodeling and Relation to Outcome: Multicenter Automatic Defibrillator Implantation Trial: Cardiac Resynchronization Therapy (2010) (310)
- Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. (1999) (308)
- Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). (2002) (305)
- Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. (2003) (300)
- Determinants of Elevated Pulse Pressure in Middle-Aged and Older Subjects With Uncomplicated Systolic Hypertension: The Role of Proximal Aortic Diameter and the Aortic Pressure-Flow Relationship (2003) (295)
- Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. (2013) (293)
- Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. (1997) (292)
- Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. (1992) (292)
- Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas (2006) (290)
- Survival with cardiac-resynchronization therapy in mild heart failure. (2014) (290)
- Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. (1999) (286)
- Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. (2014) (286)
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. (2018) (285)
- Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. (1982) (282)
- Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. (2006) (280)
- Left ventricular remodeling after acute myocardial infarction. (1995) (265)
- Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum (2018) (264)
- Albuminuria in chronic heart failure: prevalence and prognostic importance (2009) (264)
- Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. (2010) (260)
- Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program (2006) (257)
- Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program (2004) (256)
- Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction (2005) (254)
- Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. (1999) (253)
- Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. (2017) (252)
- Left Ventricular Remodeling and Ventricular Arrhythmias After Myocardial Infarction (2003) (249)
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials (2018) (248)
- Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project (2002) (244)
- Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. (2002) (244)
- Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. (2011) (243)
- Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. (2008) (242)
- Cardiac function and morphology with aging in the spontaneously hypertensive rat. (1979) (239)
- Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program (2007) (239)
- Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) (2008) (235)
- Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. (1992) (235)
- Relation Between Alkaline Phosphatase, Serum Phosphate, and All-Cause or Cardiovascular Mortality (2009) (233)
- Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. (1998) (232)
- Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial (2004) (229)
- A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) (2019) (226)
- Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT‐CRT): Design and Clinical Protocol (2005) (226)
- Omapatrilat Reduces Pulse Pressure and Proximal Aortic Stiffness in Patients With Systolic Hypertension: Results of the Conduit Hemodynamics of Omapatrilat International Research Study (2002) (224)
- Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial (2014) (221)
- Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. (2007) (220)
- Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. (1995) (215)
- Irbesartan in patients with atrial fibrillation. (2011) (215)
- Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both (2010) (214)
- Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. (1997) (214)
- Recovery of Ventricular Function after Myocardial Infarction in the Reperfusion Era: The Healing and Early Afterload Reducing Therapy Study (2001) (213)
- Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM (2007) (213)
- Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. (1996) (213)
- Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction: Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial (2014) (213)
- Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. (2004) (208)
- Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). (2008) (200)
- Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease (2005) (200)
- Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure (2005) (200)
- Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. (1994) (199)
- Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review (2002) (198)
- Pulsatile Hemodynamics in Congestive Heart Failure (2001) (198)
- Pumping Ability of the Hypertrophying Left Ventricle of the Spontaneously Hypertensive Rat (1976) (195)
- Coronary Heart Disease in Patients With Low LDL-Cholesterol: Benefit of Pravastatin in Diabetics and Enhanced Role for HDL-Cholesterol and Triglycerides as Risk Factors (2002) (193)
- Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction: The Survival And Ventricular Enlargement (SAVE) Study (2004) (193)
- Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals (2011) (189)
- Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. (2000) (186)
- Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial (2008) (186)
- Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial (2006) (185)
- Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acute myocardial infarction. (1989) (182)
- Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. (2017) (182)
- Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. (2006) (181)
- Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved (2014) (181)
- Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis (2021) (181)
- Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. (2008) (176)
- New therapeutic options in congestive heart failure: Part I. (2002) (175)
- Comparison of intensive and moderate lipid lowering with statins after acute coronary symptoms (2004) (174)
- Role of Angiotensin II in the Altered Renal Function of Congestive Heart Failure (1984) (174)
- On the restricted mean survival time curve in survival analysis (2016) (174)
- Cardiovascular Risk Assessment Using Pulse Pressure in the First National Health and Nutrition Examination Survey (NHANES I) (2001) (172)
- Aortic Diameter, Wall Stiffness, and Wave Reflection in Systolic Hypertension (2008) (172)
- Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. (2008) (170)
- Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). (1996) (170)
- Renal Function and Effectiveness of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Chronic Stable Coronary Disease in the Prevention of Events with ACE inhibition (PEACE) Trial (2006) (168)
- Effect of pravastatin in people with diabetes and chronic kidney disease. (2005) (163)
- Ventricular enlargement and reduced survival after myocardial infarction. (1987) (162)
- Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (2013) (162)
- Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collab (2000) (161)
- Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. (1991) (161)
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. (2015) (160)
- Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. (2007) (160)
- Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. (2004) (158)
- Heart failure (2005) (157)
- An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. (2004) (154)
- Cardiovascular risk in chronic kidney disease. (2004) (154)
- The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). (2006) (154)
- Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial (2011) (152)
- Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. (2012) (152)
- Renal and Systemic Hemodynamic Responses to Intravenous Infusion of Leukotriene C4 in the Rat (1984) (152)
- Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (2004) (151)
- Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. (2011) (151)
- Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme (2003) (150)
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial (2020) (148)
- Hemodynamic and Myocardial Function in Young and Old Normotensive and Spontaneously Hypertensive Rats (1973) (147)
- Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. (1995) (140)
- The contractile state as the major determinant in the evolution of left ventricular dysfunction in the spontaneously hypertensive rat. (1983) (140)
- Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction ☆ (2006) (140)
- Arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats. (1995) (140)
- An overview of contemporary etiologies of congestive heart failure. (1991) (139)
- Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction (2019) (138)
- Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial (2009) (135)
- Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. (2017) (134)
- Exercise training as therapy for heart failure: current status and future directions. (2015) (134)
- Selection Bias in the Use of Thrombolytic Therapy in Acute Myocardial Infarction (1991) (133)
- Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. (2011) (131)
- Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. (2011) (131)
- Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) (1991) (129)
- Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. (1995) (129)
- Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease (2012) (127)
- Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. (2011) (125)
- Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. (2004) (125)
- Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. (1998) (124)
- Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes (2004) (123)
- Adherence to medication according to sex and age in the CHARM programme (2009) (122)
- Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. (2000) (121)
- Atrial natriuretic factor gene expression in ventricles of rats with spontaneous biventricular hypertrophy. (1988) (119)
- Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. (2005) (118)
- Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. (1987) (116)
- Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. (2006) (115)
- Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation (2010) (115)
- Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT) (2009) (114)
- Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. (2008) (114)
- Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. (2009) (112)
- Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. (1994) (110)
- Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial (2018) (110)
- Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. (1999) (109)
- Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction (2014) (108)
- New Therapeutic Options in Congestive Heart Failure: Part II (2002) (107)
- Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction. (2009) (107)
- Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction: Results From the Valsartan in Acute Myocardial Infarction Trial (VALIANT) (2005) (107)
- Long-Term Trandolapril Treatment Is Associated With Reduced Aortic Stiffness: The Prevention of Events With Angiotensin-Converting Enzyme Inhibition Hemodynamic Substudy (2007) (106)
- Beta-adrenergic blockers and survival in heart failure. (1996) (103)
- Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction. (1997) (103)
- Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. (1999) (101)
- Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. (2015) (100)
- Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. (2008) (99)
- Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. (1982) (96)
- Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both (2010) (95)
- Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference (2017) (94)
- Left ventricular thrombus formation after first anterior wall acute myocardial infarction. (1988) (94)
- Increased left ventricular volume following myocardial infarction in man. (1986) (94)
- Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. (2006) (91)
- The frailty syndrome and outcomes in the TOPCAT trial (2018) (90)
- Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. (2019) (89)
- Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. (2005) (89)
- VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context (2003) (87)
- Mortality Rates in Trials of Subjects With Type 2 Diabetes (2012) (87)
- Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). (2013) (86)
- Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. (2014) (85)
- Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. (1999) (85)
- Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure. (1988) (85)
- Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. (2010) (85)
- Dyssynchrony, Contractile Function, and Response to Cardiac Resynchronization Therapy (2011) (85)
- Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial Clinical Investigation and Reports (1998) (85)
- Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). (2014) (84)
- Characterization of myocardial infarcts in the rat. (1980) (83)
- The Hemoglobin A 1 c Level as a Progressive Risk Factor for Cardiovascular Death , Hospitalization for Heart Failure , or Death in Patients With Chronic Heart Failure (2008) (83)
- Development of SHR hypertension and cardiac hypertrophy during prolonged beta blockade. (1977) (82)
- Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. (1998) (81)
- Which Inhibitor of the Renin–Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? (2004) (80)
- Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa: The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience (2011) (80)
- Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial. (2011) (79)
- Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) (2017) (79)
- Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. (2004) (79)
- Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. (1995) (79)
- The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. (2007) (78)
- Kidney disease and cardiovascular risk. (2007) (77)
- Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction (2011) (76)
- Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. (2006) (76)
- Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. (2016) (76)
- Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. (2005) (76)
- International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction (2015) (75)
- Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study (2012) (74)
- Influence of Albuminuria on Cardiovascular Risk in Patients With Stable Coronary Artery Disease (2007) (73)
- Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease (2019) (73)
- Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction (2008) (73)
- Alterations of cardiac performance in rats with established spontaneous hypertension. (1979) (72)
- Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). (2011) (72)
- Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling. (2004) (71)
- Augmentation index and central aortic stiffness in middle-aged to elderly individuals. (2007) (70)
- Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. (2019) (70)
- Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme (2010) (69)
- Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) (2012) (68)
- Cardiorenal hemodynamics and sodium excretion in rats with myocardial infarction. (1983) (68)
- Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus (2017) (67)
- Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone (2015) (67)
- Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme (2007) (66)
- Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. (1996) (66)
- Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (2016) (65)
- Rationale, design and baseline characteristics of the survival and ventricular enlargement trial (1991) (65)
- Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. (2019) (65)
- Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality (2018) (65)
- Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2009) (63)
- Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. (2015) (63)
- Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program (2009) (62)
- Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. (2006) (62)
- Activation of Cardiac c-Jun NH2-Terminal Kinases and p38-Mitogen-Activated Protein Kinases With Abrupt Changes in Hemodynamic Load (2001) (61)
- Predictors of Heart Failure in Patients With Stable Coronary Artery Disease: A PEACE Study (2009) (60)
- Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis. (2001) (60)
- Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis (2021) (60)
- Comparison of techniques for measuring pulse-wave velocity in the rat. (1997) (59)
- Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. (2006) (59)
- Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme (2006) (59)
- Patency of the infarct-related coronary artery and ventricular geometry. (1991) (58)
- Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19 (2020) (57)
- Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. (2019) (57)
- Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. (2021) (57)
- Left ventricular end-diastolic pressure and risk of subsequent heart failure in patients following an acute myocardial infarction. (2007) (57)
- Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. (2018) (56)
- Cardiac hypertrophy and performance of Dahl hypertensive rats on graded salt diets. (1984) (55)
- Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. (2011) (55)
- Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial (2016) (55)
- Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. (2004) (55)
- Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. (2020) (54)
- Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme (2016) (54)
- Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. (2004) (53)
- Hemodynamics of spontaneously hypertensive rats. I. Effects of pressure elevation. (1973) (53)
- Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators (2005) (53)
- Measurement of aortic input impedance in rats. (1994) (52)
- Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. (2018) (52)
- Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT‐CRT (2014) (52)
- The platelet PlA2 and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction (2001) (52)
- Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes (2017) (51)
- Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. (2006) (51)
- Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials (2018) (51)
- The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction (2010) (51)
- Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction (2020) (51)
- Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. (2007) (50)
- Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. (2008) (50)
- Echocardiography-derived left ventricular end-systolic regional wall stress and matrix remodeling after experimental myocardial infarction. (1999) (50)
- Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers. (2000) (50)
- Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. (2008) (50)
- Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. (2008) (50)
- Left ventricular remodeling after acute myocardial infarction: clinical course and beneficial effects of angiotensin-converting enzyme inhibition. (1991) (50)
- Development and prevention of congestive heart failure following myocardial infarction. (1993) (49)
- Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. (2009) (49)
- Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. (1991) (49)
- Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial (2021) (48)
- Contribution of cardiac and extra‐cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure (2018) (48)
- Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study. (2006) (48)
- Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. (2002) (48)
- Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. (2019) (48)
- Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. (2011) (47)
- Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). (2009) (47)
- Ventricular enlargement following infarction is a modifiable process. (1991) (47)
- Association Between ADAMTS1 Matrix Metalloproteinase Gene Variation, Coronary Heart Disease, and Benefit of Statin Therapy (2008) (47)
- Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. (2006) (46)
- Electromagnetic flowmetry in anesthetized rats. (1972) (46)
- Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT) (2015) (46)
- Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure (2020) (45)
- Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage. (1998) (45)
- Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. (2013) (45)
- Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. (2005) (44)
- Data monitoring committees: Promoting best practices to address emerging challenges (2017) (44)
- Ventricular performance in rats with myocardial infarction and failure. (1984) (44)
- Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. (2018) (44)
- Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial--Cardiac Resynchronization Therapy (MADIT-CRT). (2010) (44)
- Angiotensin converting enzyme inhibitors and cardiovascular remodelling. (1994) (43)
- Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints (2019) (43)
- Ventricular Remodeling Does Not Accompany the Development of Heart Failure in Diabetic Patients After Myocardial Infarction (2002) (43)
- Renal function estimation and Cockcroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart ‘OMics’ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives (2016) (42)
- Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials (2014) (42)
- Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials (2016) (42)
- Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure (2015) (42)
- Temporal dissociation of left ventricular function and remodeling following experimental myocardial infarction in rats. (1999) (41)
- Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). (2010) (41)
- Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren (2012) (41)
- Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial). (2004) (41)
- Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction. (2001) (41)
- Role of left ventricular dysfunction in neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction (1990) (41)
- Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study (2017) (40)
- Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia (2014) (40)
- Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients (2018) (39)
- Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: A systematic review ☆ (2003) (39)
- Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics (2021) (39)
- Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. (1995) (39)
- Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. (2005) (39)
- Systemic hemodynamic effects of endothelin in rats. (1990) (39)
- Impact of erythropoiesis‐stimulating agents on morbidity and mortality in patients with heart failure: an updated, post‐TREAT meta‐analysis (2010) (38)
- Systemic hemodynamic effects of leukotrienes C4 and D4 in the rat. (1983) (38)
- Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction (2021) (38)
- QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction. (2016) (38)
- Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. (2013) (37)
- Reversing cardiac hypertrophy in hypertension. (1990) (37)
- Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials (2006) (37)
- ECG alterations with progressive left ventricular hypertrophy in spontaneous hypertension. (1978) (36)
- Acute heart failure complicating acute coronary syndromes: a deadly intersection. (2004) (36)
- High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. (2008) (36)
- Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. (2008) (36)
- Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus (2020) (36)
- Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction (2013) (36)
- Ventricular morphology and pumping ability of exercised spontaneously hypertensive rats. (1978) (35)
- Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. (2015) (35)
- Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. (2012) (35)
- Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease (2015) (35)
- Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. (2016) (34)
- Treatment of Heart Failure With Preserved Ejection Fraction: Reflections on Its Treatment With an Aldosterone Antagonist. (2016) (34)
- Adrenergic mechanisms in human hypertension and in spontaneously hypertensive rats. (1975) (34)
- 1145-122 Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from CHARM (2004) (34)
- The transition to failure in the spontaneously hypertensive rat. (1997) (34)
- Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial (2018) (34)
- Klotho, fibroblast growth factor‐23, and the renin–angiotensin system — an analysis from the PEACE trial (2017) (34)
- Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction (2016) (34)
- Role of the fibrinolytic system in preventing myocardial infarction. (1995) (33)
- Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) (2013) (33)
- Pulsatile hemodynamics in hypertension. (1999) (33)
- Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. (2005) (32)
- When a question has an answer: rationale for our early termination of the HEART Trial. (1995) (31)
- Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction (2018) (31)
- Systemic and regional flow distribution in normotensive and spontaneously hypertensive young rats subjected to lifetime beta-adrenergic receptor blockade. (1978) (31)
- Heart failure: The many faces of heart failure with preserved ejection fraction (2012) (31)
- Baseline Distribution of Participants With Depression and Impaired Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (2015) (31)
- Endothelin-A Receptor Antagonism during Acute Myocardial Infarction in Rats (2000) (31)
- Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial (2018) (31)
- Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme (2005) (30)
- Angiotensin-converting enzyme inhibition in congestive heart failure: benefit and perspective. (1993) (30)
- Ejection fraction by radionuclide ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular Enlargement. (1999) (30)
- Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). (2005) (30)
- Cardiac myocyte membrane wounding in the abruptly pressure-overloaded rat heart under high wall stress. (1997) (30)
- Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. (2008) (30)
- Prevention of the development of heart failure and the regression of cardiac hypertrophy by captopril in the spontaneously hypertensive rat. (1983) (30)
- Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial (2017) (30)
- Renin-angiotensin system and cardiac rupture after myocardial infarction. (2002) (30)
- Right Ventricular Function, Pulmonary Pressure Estimation, and Clinical Outcomes in Cardiac Resynchronization Therapy (2013) (29)
- Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non‐vitamin K antagonist oral anticoagulant dose adjustment (2016) (29)
- Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. (2015) (29)
- Effect of pravastatin on blood pressure in people with cardiovascular disease (2006) (29)
- Serum Phosphate: A Novel Cardiovascular Risk Factor Even in Nonrenal Patients Relation between Serum Phosphate Level and Cardiovascular Event Rate in People with Coronary Disease. Circulation 112: 2627-2633, 2005 (2006) (28)
- C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2016) (28)
- Effect of angiotensin‐converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction—a meta‐analysis (2006) (28)
- Circumstances and Outcomes of Sudden Unexpected Death in Patients With High-Risk Myocardial Infarction: Implications for Prevention (2011) (28)
- Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. (2004) (28)
- Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2015) (27)
- Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. (2019) (27)
- Additive Beneficial Effects of Beta-Blockers to Angiotensin-Converting Enzyme Inhibitors in the Survival and Ventricular Enlargement (SAVE) Study fn1fn1This study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montrea (1997) (27)
- Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. (2014) (27)
- Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial. (2004) (26)
- Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: The CHARM Program (2006) (26)
- Effects of hypertension on cardiac performance in rats with myocardial infarction. (1982) (26)
- Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF (2020) (26)
- Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial (2018) (25)
- Heart Failure and Hypertension: Importance of Prevention. (2017) (25)
- Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration (2018) (25)
- Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. (2018) (25)
- Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. (2008) (25)
- Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) (2016) (25)
- A prospective evaluation of the angiotensin‐converting enzyme D/I polymorphism and left ventricular remodeling in the ‘Healing and Early Afterload Reducing Therapy’ Study (2002) (25)
- The Future of Clinical Trials in Cardiovascular Medicine (2016) (24)
- Ultrastructural analysis of renal papillary interstitial cell of spontaneously hypertensive rats. (1974) (24)
- The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial. (2001) (23)
- Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
- Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. (2016) (23)
- Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial (2018) (23)
- Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction. (2003) (23)
- Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. (2006) (23)
- Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. (2014) (23)
- Access to safety data--stockholders versus prescribers. (2011) (23)
- Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial (2017) (22)
- Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study. (2017) (22)
- Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. (2006) (22)
- Natural biventricular hypertrophy in normotensive rats. I. Physical and hemodynamic characteristics. (1979) (22)
- Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study. (2017) (22)
- Left ventricular hypertrophy and pressure generating capacity in aging genetically hypertensive rats. (1985) (22)
- Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT (2020) (22)
- NT‐proBNP by Itself Predicts Death and Cardiovascular Events in High‐Risk Patients With Type 2 Diabetes Mellitus (2020) (22)
- Mechanism of the negative inotropic action of leukotrienes C4 and D4 on isolated rat heart. (1985) (22)
- Left ventricular assessment in myocardial infarction: the VALIANT registry. (2005) (21)
- Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. (2000) (21)
- The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients (2014) (21)
- N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status (2019) (21)
- Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. (2019) (21)
- Inducible nitric oxide synthase and tumor necrosis factor in animal models of myocardial necrosis induced by coronary artery ligation or isoproterenol injection. (1999) (21)
- Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort. (2017) (21)
- Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. (2007) (20)
- The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. (2001) (20)
- Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2019) (20)
- Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). (2019) (20)
- Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. (2021) (19)
- Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. (2016) (19)
- Use of Statins and Aspirin to Reduce Risks of Cardiovascular Disease (2002) (19)
- Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. (2013) (19)
- Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. (1990) (19)
- The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. (1993) (19)
- Incidence and Outcomes of Pneumonia in Patients With Heart Failure. (2021) (19)
- Hemodynamics of the Spontaneously Hypertensive Rat: Effects of Isoproterenol 1 (1974) (19)
- Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks (2018) (19)
- Enhancing Trial Integrity by Protecting the Independence of Data Monitoring Committees in Clinical Trials (2014) (19)
- Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non‐sudden cardiac death in myocardial infarction survivors with heart failure (2019) (19)
- Heart failure with preserved ejection fraction: a forest of a variety of trees. (2014) (19)
- Associations Between Depressive Symptoms and HFpEF-Related Outcomes. (2020) (19)
- Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme (2015) (19)
- Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. (2004) (19)
- Lessons in Uncertainty and Humility - Clinical Trials Involving Hypertension. (2016) (18)
- Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. (1998) (18)
- Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. (2011) (18)
- Pharmacologic Regression of Cardiac Hypertrophy In Experimental Hypertension (1984) (18)
- Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. (2020) (18)
- The year in heart failure. (2004) (17)
- Composite outcomes: weighting component events according to severity assisted interpretation but reduced statistical power. (2010) (17)
- Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System (2020) (17)
- Association between mean systolic and diastolic blood pressure throughout the follow‐up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High‐Risk Myocardial Infarction Database Initiative (2018) (17)
- Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme (2010) (17)
- Prognostic use of echocardiography 1 year after a myocardial infarction. (2005) (17)
- Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. (2021) (17)
- Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. (2011) (17)
- Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. (2008) (17)
- Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. (2019) (17)
- Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). (2009) (16)
- New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment (2017) (16)
- Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction (2021) (16)
- Site selection for heart failure clinical trials in the USA (2015) (16)
- Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. (2006) (16)
- Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. (2020) (15)
- Value of the electrocardiogram in predicting left ventricular enlargement and dysfunction after myocardial infarction. (2003) (15)
- Acute effects of withdrawal of cardiac resynchronization therapy on left and right ventricular function, dyssynchrony, and contractile function in patients with New York Heart Association functional class I/II heart failure: MADIT-CRT. (2013) (15)
- Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. (2020) (15)
- Hypertension detection, treatment and control: a call to action for cardiovascular specialists. (1999) (15)
- Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo. (2008) (14)
- Myocardial infarction and heart failure-a dangerous intersection. (2002) (14)
- Predictors of sudden cardiac death in high‐risk patients following a myocardial infarction (2020) (14)
- Blood pressure in heart failure: a love-hate relationship. (2007) (14)
- Maximizing scientific knowledge from randomized clinical trials. (2010) (14)
- Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance index--Survival and Ventricular Enlargement (SAVE) experience. (2006) (14)
- Post-myocardial infarction ventricular remodeling: Animal and human studies (1994) (14)
- Effect of left ventricular sphericity on the evolution of ventricular dysfunction in rats with diffuse isoproterenol-induced myocardial necrosis. (1998) (13)
- Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial (2021) (13)
- Molecular genetics crying wolf? The case of the angiotensin-converting enzyme gene and cardiovascular disease. (1995) (13)
- Mechanistic Lessons from the Save Study (1994) (13)
- Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. (2020) (13)
- Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome (2020) (13)
- Dual renin-angiotensin system blockade and kidney disease. (2009) (13)
- Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial. (2021) (13)
- Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial (2018) (12)
- Systemic Hemodynamics and Cardiac Function in the Spontaneously Hypertensive Rat: Similarities with Essential Hypertension (1981) (12)
- Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) (2016) (12)
- Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. (2017) (12)
- Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. (2015) (12)
- CARDIOVASCULAR AND RENAL OUTCOMES OF MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN PARAGON-HF (2020) (12)
- Editor’s Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction (2018) (12)
- Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure (2022) (11)
- Physical activity and risk of cardiovascular events and all-cause mortality among kidney transplant recipients. (2020) (11)
- ASSOCIATION OF FIBROBLAST GROWTH FACTOR (FGF)-23 LEVELS WITH RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE (2012) (11)
- Streamlining cardiovascular clinical trials to improve efficiency and generalisability (2017) (11)
- Meta-analysis of individual patient data from trials of long-term ACE-inhibitor treatment after acute myocardial infarction (SAVE, AIRE, and TRACE studies) (1997) (11)
- Moving beyond our comfort zone. (2013) (11)
- Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial (2021) (11)
- Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction (2021) (11)
- The heart and conduit vessels in hypertension. (1997) (11)
- Uncertainty in the treatment of anemia in chronic kidney disease. (2005) (10)
- Aldosterone antagonism and myocardial infarction: from animals to man and back. (2003) (10)
- Characteristics of a model of myocardial infarction produced by coronary artery ligation in the rat. (1995) (10)
- Mechanism of immediate hemodynamic effects of chlorothiazide. (1975) (10)
- Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial (2022) (10)
- Leapfrogging data: no shortcuts for safety or efficacy information. (2008) (10)
- Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction (2020) (10)
- ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. (2017) (10)
- Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review. (2021) (10)
- Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations (2018) (10)
- Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. (2021) (10)
- Myocardial infarction in experimental hypertension in rats: mechanism of the reduction in blood pressure. (1980) (9)
- Selective activation of neurohormonal systems in post-infarction left ventricular dysfunction (1991) (9)
- Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF (2022) (9)
- The effect of treatment on survival in congestive heart failure (1992) (9)
- A Randomized Trial of Intensive versus Standard Blood-Pressure Control. (2021) (9)
- New Treasures from Old? EPHESUS (2004) (9)
- Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. (2006) (9)
- The decreasing incidence of left ventricular remodeling following myocardial infarction (1997) (9)
- The association of the heart failure score with mortality and heart failure hospitalizations in elderly patients: insights from the Mode Selection Trial (MOST). (2006) (8)
- B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients (2017) (8)
- National Heart, Lung, and Blood Institute and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary (2006) (8)
- Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial (2021) (8)
- SUDDEN DEATH IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A COMPETING RISKS ANALYSIS FROM THE TOPCAT TRIAL (2018) (8)
- Glomerular response to severe congestive heart failure in the rat (1983) (8)
- Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. (2021) (8)
- The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis (2017) (8)
- Moving beyond the conventional stratified analysis to estimate an overall treatment efficacy with the data from a comparative randomized clinical study (2018) (7)
- 861-2 Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin, and an early conservation initial management strategy: Results from the A phase of the A to Z trial (2004) (7)
- Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis (2022) (7)
- Evaluation and management of patients with uncontrolled systolic hypertension: is another new paradigm really needed? (2005) (7)
- Statins and Diabetes: Current Perspectives and Implications for Clinicians. (2017) (7)
- Are we asking too much of our trials? (2002) (7)
- Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan (2021) (7)
- Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction (2021) (7)
- Left ventricular hypertrophy in hypertension. (1991) (7)
- Effects of cardiac resynchronization therapy on left ventricular mass and wall thickness in mild heart failure patients in MADIT-CRT. (2013) (7)
- Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction (2020) (7)
- Influence of ejection fraction on cause‐specific mortality in heart failure with preserved ejection fraction (2018) (7)
- Treatment of diabetes mellitus: the urgent need for multifactorial interventions. (2014) (6)
- Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype. (2018) (6)
- Left ventricular size, mass, and shape: is the sum greater than the parts? (2014) (6)
- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction (2018) (6)
- Inhibitors of Angiotensin-Converting Enzyme, Angiotensin II Receptor, Aldosterone, and Renin (2009) (6)
- Infarct haemorrhage detected by cardiac magnetic resonance imaging: are we seeing the latest culprit in adverse left ventricular remodelling? (2009) (6)
- Measurement of Plasma Lipids in Patients Admitted With Acute Myocardial Infarction or Unstable Angina Pectoris (2001) (6)
- PRAISE (prospective randomized amlodipine survival evaluation) and criticism. (2013) (6)
- Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. SAVE Investigators. (1991) (6)
- Cancer in cardiovascular drug trials and vice versa: a personal perspective. (2013) (6)
- Global Differences in Heart Failure With Preserved Ejection Fraction (2021) (6)
- Erratum: Prognostic value of cardiac troponin i measured with a highly sensitive assay in patients with stable coronary artery disease (J Am Coll Cardiol (2013) 61 (1240-1249)) (2014) (6)
- Anemia treatment in chronic kidney disease: shifting uncertainty (2008) (6)
- Significance of a lateral Q wave following first anterior wall acute myocardial infarction. (1990) (6)
- Blood pressure and left ventricular dysfunction in the spontaneously hypertensive rat. (1983) (6)
- 810-1 Impact of the angiotensin-receptor blocker candesartan in preventing diabetes in patients with heart failure (2004) (6)
- The predictive value of LV systolic sphericity index, a magnification-independent assessment of LV shape (1996) (5)
- Clinical implications of left ventricular hypertrophy in systemic hypertension (1991) (5)
- Can there be any surrogate for safety (2010) (5)
- Reduction in the Risk of Heart Failure with Preventive Cardiac Resynchronization Therapy: MADIT-CRT Trial (2009) (5)
- Alterations in the electrocardiogram of spontaneously hypertensive rats by chronic antihypertensive therapy with captopril. (1982) (5)
- Comparative effects of propranolol and nadolol on renal blood flow in normal rats and rats with congestive heart failure. (1984) (5)
- Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved’ [Eur J Heart Fail 2014;16:33–40] (2014) (5)
- Diagnosis and management of coronary artery disease. (1998) (5)
- PROVE IT-TIMI 22 an Low-Density Lipoprotein Be Too Low ? he Safety and Efficacy of Achieving Very Low ow-Density Lipoprotein With Intensive Statin Therapy PROVE IT-TIMI 22 Substudy tephen (2005) (5)
- Spironolactone for heart failure with preserved ejection fraction. (2014) (5)
- Abstract 14922: Prognostic Value of Baseline BNP and NT-ProBNP and its Interaction With Spironolactone in Patients With Heart Failure and Preserved Ejection Fraction in the TOPCAT Trial (2015) (5)
- Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials (2022) (5)
- Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. (2022) (5)
- Ventricular Enlargement Following a Myocardial Infarction (1987) (5)
- Abstract 3803: Influence of Autopsy Records on Classification of Sudden Unexpected Death in Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure or Both (2009) (4)
- Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure (2022) (4)
- Adult myocyte hyperplasia: divided they fail? (1994) (4)
- ACCORD(ing) to a trialist. (2010) (4)
- Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme (2000) (4)
- The Role of Geometry in left Ventricular Remodeling After Myocardial Infarction (1995) (4)
- Guidelines and guidance in lipid modification. (2015) (4)
- Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial (2022) (4)
- Myocardial infarction, ventricular remodeling, and angiotensin-converting enzyme inhibition: where we stand today. (1998) (4)
- Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial. (2019) (4)
- Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials (2022) (4)
- Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF (2021) (4)
- Editorial commentary: The lower the LDL the better but how and how much? (2018) (4)
- Beyond the P-value and the sound bite: learning from ‘negative’ clinical trials (2017) (4)
- Prevention of post-infarction left ventricular remodeling by ACE-inhibitors. (1994) (4)
- Impaired Cardiac Performance in Rats with Long-Term Spontaneous Hypertension (1981) (4)
- Early use of beta-blockade in complicated myocardial infarction: The VALIANT trial (2003) (4)
- Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. (2019) (4)
- Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial (2020) (4)
- Apical wall stress by finite element analysis predicts subsequent left ventricular remodeling in the healing and early afterload reducing trial (1998) (4)
- Heart failure: management and prognosis (2012) (4)
- Myocardial infarct: no one size fits all. (2002) (4)
- 835-5 Candesartan improves functional class across a broad spectrum of patients with chronic heart failure: Results of the candesartan in heart failure-assessment of reduction in mortality and morbidity programme (CHARM) (2004) (4)
- Cardiac Remodeling and Its Prevention (2002) (3)
- Role of angiotensin II in the altered renal function of heart failure. (1987) (3)
- Angiotensin converting enzyme inhibition therapy following myocardial infarction. Rationale for clinical trials. (1991) (3)
- The CHARM programme (2003) (3)
- Dual renin-angiotensin system blockade in heart failure. (2009) (3)
- Prescription of Statins to Women Poses New Clinical Challenges. (2018) (3)
- Janice M. Pfeffer Memorial Lecture. (2002) (3)
- Emerging clinical challenges in the use of statins. (2013) (3)
- New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study. (2001) (3)
- The intersection between acute coronary syndrome and heart failure (2003) (3)
- Prescription of Aspirin and Statins in Primary Prevention. (2019) (3)
- Response by Pfeffer et al to Letter Regarding Article, "Heart Failure With Preserved Ejection Fraction in Perspective". (2019) (3)
- Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial (2021) (3)
- ASPIRIN IN PRIMARY PREVENTION: NEEDS INDIVIDUAL JUDGMENTS. (2020) (3)
- Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib (2021) (3)
- Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy (2022) (3)
- Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF (2022) (3)
- Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003. (2003) (3)
- Clinical Trials Involving Hypertension. (2017) (3)
- 729-4 Left Ventricular Hypertrophy and the Deletion-Insertion Polymorphism of the Angiotensin Converting Enzyme Gene (1995) (3)
- Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial (2017) (3)
- Heart and hypertension: The magnitude of the problem (1989) (3)
- 1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study (2004) (3)
- Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial (2022) (3)
- Altered sensitivity to increases in vascular resistance in rats with hypertension and myocardial infarction. (1986) (3)
- INFLUENCE OF AGE ON EFFICACY AND SAFETY OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (2020) (2)
- Abstract 20401: Cardiorenal Risks of Celecoxib, Naproxen or Ibuprofen in Arthritis Patients : A Sub-Anaylsis From the PRECISION Trial (2017) (2)
- Abstract 2208: Role of Longitudinal and Circumferential Strain Rate in the Prediction of Left Ventricular Remodeling and Prognosis After Myocardial Infarction: The VALIANT Study (2008) (2)
- Prognostic Impact of an Ischemic Etiology of Chronic Heart Failure across the Spectrum of Ejection Fractions in the CHARM Program (2012) (2)
- Health‐related quality of life outcomes in PARAGON‐HF (2022) (2)
- HMG CoA reduction in patients with average cholesterol concentrations. (2011) (2)
- COMMANDER HF - A Trial and an Answer. (2018) (2)
- 9. Statins in the treatment and prevention of cardiovascular diseases (2016) (2)
- Risk factors, mortality trends and cardiovasuclar diseases in people with Type 1 diabetes and controls: A Swedish observational cohort study (2022) (2)
- Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes (2022) (2)
- Development of a hypertensive strain of Wistar rats from previously normotensive but labile normals. (1977) (2)
- 1108-109 Low hemoglobin is an independent predictor of adverse fatal and nonfatal outcomes in both reduced and preserved systolic function chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity program (CHARM) (2004) (2)
- Abstract 2996: The Relationship of Heart Rate in the Early Post Myocardial Infarction Period and Long Term Outcome: Results From the VALsartan in Acute Myocardial iNfarcTion (VALIANT) Trial (2009) (2)
- NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia - A brief report from the ORIGIN trial. (2021) (2)
- Abstract 17975: Anemia in Heart Failure With Preserved Ejection Fraction: Insights From the TOPCAT trial (2015) (2)
- Bundle branch block is associated with worse clinical outcomes in heart failure, especially with reduced systolic function: evidence from the CHARM programme (2005) (2)
- Aspirin and the Risk of Heart Failure Hospitalization in Patients with Atrial Fibrillation and a Prior History of Heart Failure: An ACTIVE-W Analysis (2006) (2)
- Improved cardiac performance with long term reduction of blood pressure in old spontaneously hypertensive rats (1980) (2)
- A challenge to the nuclear cardiology laboratory: Imaging goals in patients after infarction (1996) (2)
- Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction (2016) (2)
- Heart Failure Updates (2003) (2)
- Importance of NT-proBNP and conventional risk factors for prediction of death in older adults with and without diabetes mellitus- a report from the Atherosclerosis Risk in Communities (ARIC) study. (2022) (2)
- INFLUENCE OF LEFT VENTRICULAR EJECTION FRACTION ON CAUSE-SPECIFIC MORTALITY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE TOPCAT TRIAL (2017) (2)
- Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. (2022) (2)
- Cholesterol and total mortality (1992) (2)
- McMurray and Pfeffer New Therapeutic Options in CHF : Part I 2101 (2002) (2)
- Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement. (1994) (2)
- Influence of Prior Heart Failure Hospitalization on Cardiovascular Events in Patients with Reduced and Preserved Ejection Fraction Bello et al: Effect of HF Hospitalization on CV Events (2017) (2)
- Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT (2021) (2)
- ASPIRIN FOR PRIMARY PREVENTION IN PATIENTS WITH TYPE 2 DIABETES. (2018) (2)
- Abstract 17352: Incidence and Predictors of Stroke in Patients with Chronic Heart Failure: Does Left Ventricular Function Matter? Insights From the CHARM Program (2011) (2)
- 923-7 Infarct Artery Patency does not Prevent LV Remodeling (1995) (2)
- Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF (2021) (2)
- Left Ventricular Assessment in Myocardial Infarction (2013) (2)
- Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial (2020) (2)
- Statins: A brief summary (2001) (2)
- Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome. (2022) (1)
- Transition to Cardiac Failure in Spontaneously Hypertensive Rats (1984) (1)
- Abstract 17827: Impact of Spironolactone on Profibrotic Markers in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT) (2016) (1)
- Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age (2021) (1)
- Influen ce of diabetes mellitus on development of heart failure following anterior myocardial infarction (2014) (1)
- Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients with Heart Failure. (2023) (1)
- Outpatient diuretic intensification as endpoint in HFpEF trials: an analysis from TOPCAT. (2021) (1)
- Scientists on the Spot: The cycle of basic science and clinical trials. (2019) (1)
- Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. (2020) (1)
- From practice changing to hypothesis generating: a virtuous cycle. (2019) (1)
- Aliskiren in type 2 diabetes and cardiorenal end points. (2013) (1)
- Judgement over an arbitrary line (2018) (1)
- Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction? (2000) (1)
- Chronic renal disease and cardiovascular risk - Reply (2005) (1)
- Impact of known and newly diagnosed diabetes mellitus after a myocardial infarction (2003) (1)
- Modifiable Risk Factors for Stroke in High-Risk Patients following Acute Myocardial Infarction: Insights from the VALIANT Study (2004) (1)
- Abstract 3594: Lack of Interaction between Angiotensin Receptor Blocker and Aspirin in Patients with Heart Failure (2006) (1)
- Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 116: 2687-2693, 2007. (2008) (1)
- Early left ventricular function predicts subsequent ventricular remodeling following myocardial infarction in rats (1996) (1)
- Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits Part 1 - Health Benefits (2006) (1)
- Rampiril reduced long-term mortality in patients with clinical heart failure following acute MI. (1997) (1)
- Weight loss (but not weight gain) is a strong predictor of mortality in chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program (2005) (1)
- Abstract 1253: Increased Red Blood Cell Distribution Width is Associated with Greater Risk of All-Cause, Cardiovascular and Non-Cardiovascular Mortality in a Large Community-Based Cohort (2008) (1)
- Searching for treatments of heart failure with preserved ejection fraction: matching the data to the question. (2014) (1)
- CONFIRMATION OF KEY TREAT FINDINGS IN RED-HF, A PLACEBO CONTROLLED HEART FAILURE TRIAL (2014) (1)
- MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND LEFT VENTRICULAR EJECTION FRACTION≥45%: INSIGHTS FROM PARAGON-HF (2020) (1)
- Abstract 844: No Clear Association Between Candidate Gene Variants and Outcomes in 3239 Patients with Chronic Heart Failure: Results from the CHARM Program (2008) (1)
- Epidemiology and Prevention Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Statement From the American Heart Association Councils on Kidney in Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A (2011) (1)
- Influence of Age on the Efficacy and Safety of Spironolactone in Heart Failure with Preserved Ejection Fraction (2019) (1)
- Corrigendum to ‘Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial’ [Eur J Heart Fail 2009;11:795–801] (2010) (1)
- Abstract 2249: Effects of Mechanical Asynchrony on Mitral Regurgitation After Acute Myocardial Infarction: The VALIANT Echo Study (2008) (1)
- Prognostic Impact of Cardiovascular versus Noncardiovascular Hospitalizations in Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT. (2022) (1)
- Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial (2022) (1)
- Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes (2022) (1)
- Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials. (2023) (1)
- Ventricular function during early left ventricular hypertrophy of the intact spontaneously hypertensive rat. (1973) (1)
- Inhibiting the Renin Angiotensin Aldosterone System in Patients with Heart Failure and Myocardial Infarction (2009) (1)
- EFFECT OF PRAVASTATIN IN PEOPLE WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS: PD.8 (2005) (1)
- NT-PROBNP AND HSTNT IMPROVE CARDIOVASCULAR RISK PREDICTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY OR CARDIOVASCULAR DISEASE OR BOTH (2014) (1)
- EFFECT OF BASELINE RIGHT VENTRICULAR FUNCTION ON OUTCOMES AFTER CRT: AN ANALYSIS OF THE MADIT-CRT POPULATION (2011) (0)
- Special Lecture (2004) (0)
- Abstract 1876: Incremental Value of Echocardiographic Assessment Beyond Clinical Evaluation for Prediction of Death and Development of Heart Failure After Myocardial Infarction in Patients with Left Ventricular Dysfunction, Heart Failure, or Both (2007) (0)
- A practical, validated model for prediction of risk in chronic heart failure (2006) (0)
- EResearch Advances Series Ventricular Remodeling After Myocardial Infarction Experimental Observations and Clinical Implications (2005) (0)
- 62A Decision rules for predicting future lipid values in a cholesterol reduction clinical trial (1994) (0)
- Experimental Studies Temporal and Dissociation of Left Ventricular Function Remodeling Following Experimental Myocardial Infarction in Rats (1999) (0)
- The rationale for combined use of diuretics, digitalis, and vasodilators in congestive heart failure (2005) (0)
- Abstract 12684: Cardiorenal Outcomes and the Efficacy of Darbepoetin in Patients With Heart Failure, Reduced Ejection Fraction, Anemia and Advanced Chronic Kidney Disease (2014) (0)
- Lack of Association of Exercise Testing With Coronary Stent Closure (2000) (0)
- Use of the angiotensin antagonist (AT1) for the reduction of post-myocardial infarktmorbiditet and mortality (1993) (0)
- Heart, Lung, and Blood Institute Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and (2006) (0)
- The CHARM programme. Authors' reply (2003) (0)
- Clinical Translation of Cardiovascular Biomarkers — A Long and Uncertain Road (2022) (0)
- The CHARM Program: Study Design Leads to Findings of Clinical and Public Health Importance (2007) (0)
- 1142-177 Antecedent hypertension and the risk of subsequent left ventricular remodelling after acute myocardial infarction: Insights from the survival and ventricular enlargement trial (2004) (0)
- Impact of combining fatal and nonfatal endpoints in heart failure trials (2002) (0)
- Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. (2023) (0)
- The role of angiotensin II (AII) and cyclooxygenase products in mediating the systemic and renal vascular responses to leukotriene C4 (LTC4) infusion in the rat (1984) (0)
- GENDER ALTERS THE RELATIONSHIP BETWEEN QRS WIDTH AND MECHANICAL DYSSYNCHRONY: MADIT-CRT (2011) (0)
- BLACK RACE ASSOCIATED WITH WORSE OUTCOMES IN AMBULATORY HEART FAILURE-PRESERVED EJECTION FRACTION PATIENTS (2015) (0)
- Relationship between Change in Ventricular Size and Function and BNP in Patients Undergoing CRT Therapy: MADIT-CRT (2011) (0)
- Valsartan, captopril, or both in myocardial infarction - Reply (2004) (0)
- RESTING HEART RATE AND CHANGES IN HEART RATE ARE ASSOCIATED WITH ADVERSE OUTCOME IN HEART FAILURE PATIENTS WITHOUT ATRIAL FIBRILLATION: AN ANALYSIS OF THE CHARM PROGRAM (2014) (0)
- 588 Differences between younger and older patients with chronic heart failure. Baseline demographics from CHARM (2003) (0)
- High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention From the American Heart Association Councils on Kidney in Cardiovascular Disease, Kidney Disease as a Risk Factor for Development of Cardiovascular Disease : A Statement (2013) (0)
- Baseline Characteristics of the Patients in the Two Treatment Groups * Placebo (2005) (0)
- On expectations: address to the ochsner clinic graduating residents and fellows on june 6, 2006. (2006) (0)
- Abstract 16477: Sacubitril/valsartan as a Treatment for Resistant Hypertension in Patients With Heart Failure and Preserved Ejection Fraction (2020) (0)
- Decreased Global Longitudinal Strain in Diabetics With Preserved Ejection Fraction Post-Myocardial Infarction: A VALIANT Echo Sub-study (2009) (0)
- Abstract 3169: Increase in Risk of Death in Early Months Following Hospitalization for Heart Failure: Observations from the CHARM Program (2006) (0)
- Sequential hemodynamic and pressure volume changes in myo cardial infarction in rats (1980) (0)
- Trajectory and correlates of pulmonary congestion by lung ultrasound in patients with acute myocardial infarction: Insights from PARADISE-MI. (2023) (0)
- Possible beneficial interaction between statins and combination anglotensin receptor blocker (ARB) and ACE inhibitor treatment in patients with myocardial infarction: A post hoc analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT) (2005) (0)
- Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT (2016) (0)
- 162-LB: Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome—The ELIXA Biomarker Study (2022) (0)
- Renal Denervation for Resistant Hypertension (2014) (0)
- EFFECTS OF SACUBITRIL/VALSARTAN VERSUS VALSARTAN ON RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH PRESERVED EJECTION FRACTION: PARAGON-HF (2022) (0)
- Advanced heart failure in perspective (2016) (0)
- Coronary Artery Disease ngina Pectoris Prior to Myocardial nfarction Protects Against ubsequent Left Ventricular Remodeling (2016) (0)
- Abstract 16989: Impaired Systolic Function Assessed by Strain Imaging Predicts Cardiovascular Morbidity and Mortality in Heart Failure with Preserved Ejection Fraction (2014) (0)
- Pravastatin reduced risk of death from CHD and other cardiovascular events among patients with a history of MI or unstable angina (1999) (0)
- Pharmacologic advances in long-term heart failure management. (2004) (0)
- Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction (2016) (0)
- Abstract 294: Association Between Exercise Frequency, Performance, and Health-Related Quality of Life in Heart Failure Patients (2013) (0)
- The association of the heart failure score with mortality and hospitalizations in pacemaker patients (2003) (0)
- Abstract 10291: Fibroblast Growth Factor (FGF)-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease (2013) (0)
- Th-P16:264 impact of a major randomized clinical trial on LDL cholesterol levels in the aggressive reduction of inflammation stops events (ARISE) trial (2006) (0)
- Abstract 3477: Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction (2006) (0)
- Updates on Aspirin in Primary Prevention of Cardiovascular Disease Create New Clinical and Policy Challenges (2021) (0)
- lcohol Consumption and Prognosis n Patients With Left Ventricular Systolic ysfunction After a Myocardial Infarction (2016) (0)
- Abstract 2594: Post Myocardial Infarction Hypertension and Cardiovascular Outcomes in Patients with Left Ventricular Dysfunction, Heart Failure, or Both Following Acute Myocardial Infarction (2006) (0)
- Progressive Ventricular Remodeling in Response (2005) (0)
- Abstract 12905: Association Between Renal Function and Myocardial Contractile Function following Myocardial Infarction-The VALIANT Echo Substudy (2011) (0)
- Abstract 17890: Regional Differences in Cardiac Biomarker Profile and Effect of Spironolactone in Patients With Heart Failure and Preserved Ejection Fraction Enrolled in the TOPCAT Trial (2016) (0)
- Evidence‐Based Decision Making: Patient–Physician Interface (2010) (0)
- Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs. (2022) (0)
- Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial (2022) (0)
- Body Mass Index and Prognosis in Patients With Chronic Heart Failure Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program Heart Failure (2007) (0)
- The patient with metabolic disorders and/or cardiovascular disease: New and emerging concepts (2001) (0)
- Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial (2006) (0)
- Highlights of the 52 nd Annual Scientific Session of the American College of Cardiology — March 30 – April 2 , 2003 (2016) (0)
- Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study (2022) (0)
- The target hemoglobin range recommended by the Anaemia Working Group of the European Renal (2011) (0)
- Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin The Cholesterol and Recurrent Events (CARE) Study Clinical Investigation and Reports (1998) (0)
- in Patients with Type 2 Diabetes and Acute Coronary Syndrome (2015) (0)
- Abstract 15181: Predictors of Mortality and Morbidity in Patients With Chronic Heart Failure - Analysis of Red-HF Trial (2014) (0)
- Abstract 17063: Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure (2020) (0)
- Abstract MP28: Filtration Markers, Cardiovascular Disease and All-cause Mortality in Kidney Transplant Recipients: The FAVORIT Trial (2016) (0)
- Prior and Incident Myocardial Infarction in HFpEF: A Pooled, Patient-Level Analysis of 3 Contemporary Clinical Trials with 8,916 Patients (2019) (0)
- DECLINE IN ESTIMATED GLOMERULAR FILTRATION RATE FOLLOWING SACUBITRIL/VALSARTAN INITIATION IN PATIENTS WITH HEART FAILURE: INSIGHTS FROM PARAGON-HF AND PARADIGM-HF (2023) (0)
- P6178Prognostic importance of pulmonary pressure in heart failure with preserved ejection fraction (2017) (0)
- Issues of protocol modification after initiation of a large multi-center trial (1998) (0)
- The era of devices? Biventricular pacing and implantable cardioverter-defibrillators (2003) (0)
- The effect of valsartan, captogril, or both on left ventricular size and function following high-risk MI: the VALIANT echo study (2004) (0)
- UTILITY OF BASELINE AND FOLLOW-UP CARDIOVASCULAR PHYSICAL EXAMS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: TOPCAT (2019) (0)
- Trial Levels : Subgroup Analyses in the Cholesterol And Recurrent Events ( CARE ) Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and (1998) (0)
- Response to Wave Reflection in Systolic Hypertension: Smaller Stature, Shorter Aorta: Higher Pulse Pressure? and Questions Regarding the Aortic Measurements of Mitchell et al (2008) (0)
- History of stroke in patients with heart failure: prevalence, baseline characteristics and clinical outcomes (2022) (0)
- The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis (2017) (0)
- Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein Clinical Investigation and Reports (1999) (0)
- Title: Analysing recurrent hospitalisations in heart failure: a review of statistical methodology, with application to CHARM-Preserved Short Title: Rogers et al, Analysing recurrent hospitalisations (2015) (0)
- Post myocardial infarction (MI) management patterns of pattents in the survival and ventricular enlargement (SAVE) study at Canadian and US Centers (1990) (0)
- Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure (2022) (0)
- Abstract 3739: The Influence of Albuminuria on Mortality in Patients with Stable Coronary Artery Disease (2007) (0)
- P-450: Prognostic information derived from blood pressure indices in patients with left ventricular systolic dysfunction early post-myocardial infarction (2003) (0)
- Women with heart failure are less likely to receive ACE-inhibitors: Findings from the SPICE (Study of patients intolerant of converting enzyme inhibitors) registry (1999) (0)
- RELATION BETWEEN RENAL FUNCTION AND RESPONSE TO PREVENTIVE CARDIAC RESYNCHRONIZATION THERAPY IN MADIT-CRT (2010) (0)
- Abstract 19414: Influence of Diabetes on Post-Myocardial Infarction Left Ventricular Remodeling and RAAS Inhibition with Aliskiren (2010) (0)
- Learning From Major Clinical Trials: Bending Without Breaking. (2017) (0)
- Oxford Textbook of Advanced Heart Failure and Cardiac Transplantation (2016) (0)
- Conduit vessel stiffness is increased in central but not peripheral conduit arteries in adults with essential hypertension (2002) (0)
- Response to Letter Regarding Article, “Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure” (2008) (0)
- Abstract 12574: Relationship between Baseline Dyssynchrony, Contractile Function and Primary Outcome in MADIT-CRT (2010) (0)
- RED CELL DISTRIBUTION WIDTH IS AN INDEPENDENT PREDICTOR OF OUTCOMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: AN ANALYSIS OF THE PARAGON-HF TRIAL (2023) (0)
- Response to The J-Point Revisited (2008) (0)
- Abstract 12633: Coronary Artery Disease is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes, and Anemia: An Analysis of the TREAT Trial (2014) (0)
- Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in heart failure and high risk myocardial infarction (2003) (0)
- Abstract 2874: Sudden Cardiac Death in Patients with Stable Coronary Disease and Preserved Left Ventricular Systolic Function (2007) (0)
- Varied origins of promising hypotheses in cardiovascular medicine (2018) (0)
- Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". (2019) (0)
- Abstract 3142: Predictors of Heart Failure in Patients with Stable Coronary Artery Disease and Preserved Ejection Fraction (2007) (0)
- Geographic Differences in Patients With Acute Myocardial Infarction in The PARADISE-MI Trial. (2023) (0)
- The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial (2022) (0)
- Assessment of Intrinsic Cardiac Function, Myocardial Blood Flow and Metabolism in Patients Supported on Mechanical Circulatory Assist Devices (2011) (0)
- Abstract 11159: Prolonged QRS Duration Predicts Outcomes in Heart Failure With Preserved Ejection Fraction (2015) (0)
- Progression from Hypertension to Heart Failure: Mechanisms, Epidemiology, and Prevention (2006) (0)
- Greater Cardiac Hypertrophy in Hypertensive Rats (2016) (0)
- New section in Circulation: implications of contemporary clinical trials. (2010) (0)
- Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction - Results from the Valsartan in Acute Myocardial Infarc (2005) (0)
- CHANGES IN LV CONTRACTILITY AND DYSSYNCHRONY AFTER 12 MONTHS OF RESYNCHRONIZATION THERAPY ON SUBSEQUENT OUTCOMES: MADIT-CRT (2011) (0)
- INSULIN, LIXISENATIDE, AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME (2020) (0)
- Abstract 14782: Impact of Black Race on Progression to End-Stage Renal Disease Despite Similar Outcomes for Cardiovascular Morbidity and Mortality: The TREAT Study (2013) (0)
- Implications of Contemporary Clinical Trials ACCORD(ing) to a Trialist (2010) (0)
- Prognostic importance of NT-proBNP following high-risk myocardial infarction in the PARADISE-MI Trial (2022) (0)
- Abstract 17498: Prognostic Importance of Novel Cardiac and Renal Biomarkers in Patients With Heart Failure, Reduced Ejection Fraction and Anemia (2014) (0)
- TOPCAT: Effects of Spironolactone on CV Outcomes in Patients with Heart Failure with Preserved Ejection Fraction (2013) (0)
- velocity in the rat Comparison of techniques for measuring pulse-wave (2015) (0)
- Changes in local curvature accompany left ventricular enlargement following anterior myocardial infarction (1990) (0)
- Impact of diabetes on clinical, echocardiographic, and electrocardiographic characteristics of myocardial infarction (2003) (0)
- INFLUENCE OF DIASTOLIC FUNCTION FOLLOWING MYOCARDIAL INFARCTION ON CLINICAL OUTCOMES (2011) (0)
- P-41: Augmentation index and central aortic stiffness in middle-aged and older persons (2005) (0)
- DYSGLYCEMIA, EJECTION FRACTION, AND THE RISK OF HEART FAILURE OR CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME (2019) (0)
- 1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event (2020) (0)
- Pharmacologic management of advanced heart failure (2016) (0)
- Sex bias in the management of coronary artery disease (1990) (0)
- Abstract 17176: Burden and Prognostic Importance of Heart Failure Signs and Symptoms - Differences in Heart Failure With Preserved versus Reduced Ejection Fraction (2020) (0)
- CARDIAC TROPONIN I AND B-TYPE NATRIURETIC PEPTIDE PREDICT CLINICAL OUTCOMES IN STABLE RENAL TRANSPLANT RECIPIENTS (2014) (0)
- Hemodynamic effects of mebutamate in spontaneously hypertensive rats. (1975) (0)
- 1 C-Reactive Protein and Risk of End-Stage Renal Disease – Results from TREAT ( Trial to Reduce cardiovascular Events with Aranesp Therapy ) (2016) (0)
- 594 Differences between diabetic and non‐diabetic patients with chronic heart failure. Baseline demographics from CHARM (2003) (0)
- myocardial infarction Right ventricular dysfunction and risk of heart failure and mortality after (2011) (0)
- 2-OR: Impact of N Terminal Pro B-Type Natriuretic Peptide and High Sensitivity Cardiac Troponin on the Prediction of Death and Cardiovascular Events in High-Risk Patients with Type 2 Diabetes (2020) (0)
- Abstract P329: Prospective Association of Serum Uromodulin and Cardiovascular Disease in Chronic Kidney Transplant Receipents (2018) (0)
- 1.P.149 Pravastatin prevents stroke in older patients (1997) (0)
- Abstract 3150: Renal Dysfunction Influences the Relationship Between Left Ventricular Systolic Dysfunction and Survival in the Post-Myocardial Infarction Patient (2007) (0)
- Preventive Lessons from Hypertension and Myocardial Infarction: Treating Asymptomatic Individuals to Lower the Risk for Subsequent Cardiovascular Events (2014) (0)
- 1099-89 The incidence of clinically unrecognized myocardial infarction in patients with type 2 diabetes, hypertension, and nephropathy (2004) (0)
- Predicting mortality and morbidity in chronic heart failure independent of left ventricular systolic function: Results from the CHARM program (2004) (0)
- 1030-9 An Acute Increase in Hemodynamic Load Produces Plasma Membrane Wounding of Cardiac Myocytes In Vivo (1995) (0)
- Implications of EMPHASIS-HF for Clinical Practice (2020) (0)
- OR-37: Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension. Results of the conduit hemodynamics of omapatrilat international research (CHOIR) study (2002) (0)
- PCV65 CHANGE IN HEALTH-RELATED QUALITY OF LIFE FOLLOWING NON-FATAL CARDIOVASCULAR EVENTS IN POST-MYOCARDIAL INFARCTION PATIENTS (2008) (0)
- PARADISE-MI – event rates and treatment effect of sacubitril/valsartan v ramipril by the presence or absence of transient pulmonary congestion and/or LVEF less or greater than 40 (2022) (0)
- The CHARM programme - Reply (2003) (0)
- Abstract 16658: Serum Potassium and Risk of Death in Patients With HFpEF: An Analysis of PARAGON-HF (2020) (0)
- RELATIVE APICAL SPARING PATTERN IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (THE PARAGON-HF AND TOPCAT TRIALS) (2021) (0)
- The Effect of Crt on Rv Function (rvf) Clinical Perspective on P 442 (0)
- Effects of captopril on mortality and morbidity rates in patients with left ventricular dysfunction following myocardial infarction: Results of survival and ventricular hypertrophic studies (1993) (0)
- Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials (2004) (0)
- Cardiac function and heart failure. (2003) (0)
- Use of an angiotensin (AT1) to reduce morbidity and post-myocardial infarction mortality. (1993) (0)
- MINI-FOCUS ISSUE: HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) (0)
- Quantifying and Interpreting the Prediction Accuracy of Models for the Time of a Cardiovascular Event-Moving Beyond C Statistic: A Review. (2023) (0)
- New Therapeutic Options in Congestive Heart Failure: Part I Clinical Cardiology: New Frontiers (2002) (0)
- Future directions in advanced heart failure (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Marc Allan Pfeffer?
Marc Allan Pfeffer is affiliated with the following schools:
